Related Experiment Video

Updated: Sep 8, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval

Hollis Viray1, David F McDermott1, David J Einstein1

  • 1Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Expert Review of Anticancer Therapy
|June 14, 2022
PubMed
Abstract

Insights

Tivozanib is a targeted therapy for advanced renal cell carcinoma (RCC). It is recommended for patients who have not responded to other treatments, including immune checkpoint inhibitors.

Area of Science:

  • Oncology
  • Pharmacology
  • Nephrology

Background:

  • Tivozanib is a selective vascular endothelial growth factor receptor (VEGFR)-inhibitor for advanced renal cell carcinoma (RCC).
  • Preclinical and early clinical studies indicated tivozanib's potential for potent VEGFR inhibition with reduced off-target toxicities.
  • The FDA approved tivozanib in March 2021 for third- and fourth-line treatment of relapsed, refractory RCC based on the TIVO-3 trial.

Purpose of the Study:

  • To review existing literature on tivozanib for advanced renal cell carcinoma (RCC).
  • To provide expert opinion on the optimal use of tivozanib in current and future clinical practice for RCC treatment.

Main Methods:

  • Literature review of existing studies on tivozanib.
  • Analysis of clinical trial data, including the TIVO-3 trial.
  • Expert commentary on treatment landscape and future directions.

Main Results:

  • Tivozanib is approved for relapsed, refractory RCC in third- and fourth-line settings.
  • Questions remain regarding optimal incorporation into the current RCC treatment paradigm.
  • Tivozanib may be considered after progression on immune checkpoint inhibitors (ICIs) and nonselective VEGFR-tyrosine kinase inhibitors (TKIs).

Conclusions:

  • Tivozanib is a valuable option for later-line treatment in relapsed, refractory RCC.
  • Future trials exploring combination therapy with ICIs may position tivozanib earlier in RCC treatment.
  • The role of tivozanib in RCC treatment is expected to evolve.
Keywords:
TivozanibVEGFR inhibitorrenal cell carcinomaselective VEGF inhibitiontargeted therapy

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
321
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
310
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
737
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
262